Table 2.
Potential Receptors Other Than SS Receptors for Clinical Use
| Peptide | Receptor Subtypes | Tumor Expression | Radiolabeled Peptides |
|---|---|---|---|
| Bombesin/GRP | GRP-R | Prostate cancer, breast cancer, GISTs, SCLC |
99mTc-bombesin 111ln-bombesin, 68Ga-bombesin |
| CCK/gastrin | CCK2 | MTC, insulinoma, SCLC, GISTs | 111In-DTPA-minigastrin |
| 99Y-minigastrin | |||
| GLP-1 | GLP-1-R | Insulinoma, gastrinoma | 123I-GLP-1 |
| Neuropeptide-Y | NPY-R | Breast cancer, ovarian and adrenal tumors | 99mTc-neuropeptide Y |
| Neurotensin | NT-R1 | Exocrine pancreatic cancer, Ewing sarcoma, meningioma | 99mTc-neurotensin |
| Substance P | NK1 | Glial tumors | 90Y-DOTAGA-Substance P |
| VIP | VPAC1 | Gastro-intestinal and other epithelial cancers |
123I-VIP 99mTc-TP3654 |
GRP-R, gastrin releasing peptide-receptor; CCK, cholecystokinin; GLP, glucagon-like peptide; VIP, vasoactive intestinal peptide; VPAC, VIP-pituitary adenylate cyclase-activating polypeptide; NK, neurokinin; GISTs, gastrointestinal stromal tumors.
Adapted from Rufini et al. Semin Nucl Med 36:228-247